长春瑞滨联合卡培他滨治疗蒽环类及紫杉类耐药的转移性三阴乳腺癌的临床观察

Vinorelbine Combined with Capecitabine in Triple Negative Metastatic Breast Cancer Patients

目的观察长春瑞滨联合卡培他滨治疗蒽环类及紫杉类耐药的转移性三阴性乳腺癌患者的疗效和不良反应。方法 32例蒽环类及紫杉类耐药的复发转移性三阴性乳腺癌患者接受长春瑞滨联合卡培他滨化疗,长春瑞滨25mg/m2,静脉滴注,第1天和第8天,采用深静脉穿刺置管技术静脉滴注;卡培他滨825～1000mg/m2,口服,每天2次,第1～14天;21d重复。统计分析其疗效与不良反应。结果 32例患者共接受152个周期治疗,中位治疗周期数为4个周期(2～6个周期);11例患者获得部分缓解(PR,占34.4%),9例患者获得稳定(SD,占28.1%),其中5例患者稳定维持6个月以上;12例患者获进展(PD,占37.5%)。总有效率(CR+PR)34.4%(11/32),疾病控制率(PR+SD)62.5%(20/32),中位疾病进展时间(TTP)为5.4个月。常见不良反应为骨髓抑制,恶心、呕吐和手足综合征等。结论长春瑞滨联合卡培他滨方案近期疗效好,毒性可以耐受,可作为蒽环类及紫杉类耐药的转移性三阴性乳腺癌患者治疗的选择。

Objective To evaluate efficacy and toxicity of combination chemotherapy of vinorelbine and capecitabine for anthracycline-and taxaneresistant metastatic triple negative breast cancer（TNBC）.Methods Thirty-two cases of anthracycline-and taxane-resistant metastatic TNBC patients received vinorelbine 25 mg /m2on day 1 and day 8,and capecitabine 825 mg /m2-1000 mg /m2 twice a day on day 1 through 14.Treatment was repeated every 21 days and all patients received at least 2 cycles of chemotherapy.Results In total,152 cycles were given.The median number of treatment was 4 cycles（2-6 cycles）.PR 37.5%,SD 28.1%,including 5 patients maintained SD≥6 months,PD 37.5%.The median time to progression was 5.4 months.Myelosuppression,gastrointestinal tract reaction and hand-foot syndrome were the most common toxicities.Conclusion Combination therapy of vinorelbine and capecitabine is an effective and well tolerated regimen in anthracycline-and taxane-resistant metastatic TNBC patients.